Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
about
Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction networkEqual Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?Proteasome inhibitors against amelanotic melanoma.A compound chimeric antigen receptor strategy for targeting multiple myeloma.
P2860
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@en
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@nl
type
label
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@en
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@nl
prefLabel
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@en
Outcomes of multiple myeloma p ...... lenalidomide, and carfilzomib.
@nl
P2093
P2860
P1433
P1476
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
@en
P2093
Ariana Berenson
Benjamin Eades
James R Berenson
James Wang
Jillian Gottlieb
Kyle A Udd
Nika Manik Harutyunyan
Ran Halleluyan
Regina Swift
Shahrooz Eshaghian
P2860
P304
P356
10.1007/S00277-016-2889-2
P577
2016-12-08T00:00:00Z